Detalhe da pesquisa
1.
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
N Engl J Med
; 387(23): 2113-2125, 2022 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477031
2.
A prediction model for response to immune checkpoint inhibition in advanced melanoma.
Int J Cancer
; 154(10): 1760-1771, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38296842
3.
BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Cancer
; 130(9): 1673-1683, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38198485
4.
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.
Int J Cancer
; 153(2): 389-398, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36843260
5.
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
Int J Cancer
; 152(12): 2493-2502, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36843274
6.
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Ann Surg Oncol
; 30(1): 573-586, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36203067
7.
Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.
Int J Cancer
; 150(2): 317-326, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34520567
8.
The unfavorable effects of COVID-19 on Dutch advanced melanoma care.
Int J Cancer
; 150(5): 816-824, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34605003
9.
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
Ann Intern Med
; 174(5): 641-648, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33587686
10.
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
Br J Cancer
; 124(7): 1222-1230, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33495600
11.
Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
Cancer Immunol Immunother
; 70(11): 3123-3135, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33774697
12.
Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.
Anticancer Drugs
; 32(5): 589-591, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33587356
13.
Real-world outcomes of advanced melanoma patients not represented in phase III trials.
Int J Cancer
; 147(12): 3461-3470, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32559817
14.
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
Br J Cancer
; 128(5): 707-710, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564561
15.
ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Ann Surg Oncol
; 30(1): 587-588, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36319872
16.
Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.
Anticancer Drugs
; 29(6): 579-588, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29634490
17.
Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
Anticancer Drugs
; 29(6): 572-578, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29659371
18.
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
Br J Cancer
; 126(9): 1362, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35256756
19.
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
Br J Cancer
; 124(10): 1746, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33723402
20.
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.
EClinicalMedicine
; 69: 102485, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38370537